Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RECEIVED. SECRETARY OF THE SENATE

02 MAR 26 PM 3:59

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

Registrant Name								
Alpine Group, Inc.								
2. Registrant Address ☐ Check if diffe Address 660 Pennsylvania Aven City Washington	rent than previously reported ue, SE State/Zip (or Country)	Suite 201 DC 20003						
3. Principal Place of Business (if different fi	rom line 2)							
City	State/Zip (or Country)							
4. Contact Name	Telephone E-n	nail (optional)	5. Senate ID#					
Carla Haywood	548-2315 ch	aywood@alpinegroup.com	1171-90					
7. Client Name Self		6. House ID						
DuPont Pharmaceuticals Comp	any		31749006					
10. Check if this is a Termination Rel	·		11. No Lobbyii					
12. Lobbying F.	irms	13. Organiza	tions					
INCOME relating to lobbying activ period was:	ities for this reporting	EXPENSES relating to lobbying activities for this repo period were:						
Less than \$10,000 □		Less than \$10,000 □						
\$10,000 of more 🔼 🚈	0,000.00 come (nearest \$20,000)	\$10,000 or more	xpenses (nearest \$20,					
Provide a good faith estimate, round \$20,000 of all lobbying related incor		14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of o						
(including all payments to the registr	ant by any other entity	☐ Method A. Reporting amounts using LDA definition						
for lobbying activities on behalf of the	ie chent).	☐ Method B. Reporting amounts under section 6033 the Internal Revenue Code						
		☐ Method C. Reporting amounts under section 162(e Internal Revenue Code						
Signature / Well Lague	pel:	Date	002					
	\ \	, de la companya del companya de la companya del companya de la co						

_ rage

Registrant Name:	Alpine Group, Inc.	
Client Name:	DuPont Pharmaceuticals Company	· · · · · · · · · · · · · · · · · · ·
engaged in lobbyi information as rec	ng on behalf of the client during the reporting the reporting the stack additional page(s) as needed	to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide.
	bying issues A issues relating to substitution of NTI di	ugs and patient notification of switching of NTI drugs.
House of Re Senate	Congress and Federal agencies contacted epresentatives the individual who acted as a lobbyist in this	☐ Check if None
Name		Covered Official Position (if applicable)
White, Rich	ard	
	ich foreign entity in the specific issues listed	
Signature	accepted wood	Date 3/26/2002

n.,

ragi	